Apelian David 4
4 · Eiger BioPharmaceuticals, Inc. · Filed Feb 2, 2023
Insider Transaction Report
Form 4
Apelian David
Director
Transactions
- Award
Stock Option (Right to Buy)
2023-01-31+170,000→ 170,000 totalExercise: $1.65Exp: 2033-01-31→ Common Stock (170,000 underlying)
Footnotes (1)
- [F1]The option vests as to 113,900 shares upon the earlier to occur of (i) on the six-month anniversary of December 14, 2022 or (ii) the Company's appointment of a full-time non-interim Chief Executive Officer, and as to the remaining 56,100 shares in six equal monthly installments measured from December 14, 2022, subject to the Reporting Person's continuous service as of each such date.